The phase I/II trial is being initiated at The University of Texas MD Anderson Cancer Center, and is the first time researchers will be able to test the drug on a significant population of adult patients with difficult-to-treat relapsed or refractory cases of acute lymphocytic leukemia.
Patients with relapsed or refractory acute lymphocytic leukemia typically develop cancer cells that are resistant to the currently-approved drugs, and are therefore in desperate need of a drug that overcomes this resistance.
“L-Annamycin is a next-generation drug with the potential to work in these patients who have become resistant to other drugs,” said Dr Gary Jacob, CEO and CSO of Callisto. “We hope that further demonstrations of L-Annamycin’s efficacy and safety will pave the way to rapid approval of this drug.”